ATRX and central nervous system cancer: In conclusion, the TMM status in gliomas cannot be determined simply on the basis of underlying telomere-related genetic signatures; therefore, future researchers should also consider defining this status by directly measuring telomerase enzyme activity and ALT and should not limit TMM by representing ATRX or TERT mutation as definitive indicators.